The scientific programme of 2025 at a glance
If you're looking to plan your travel, please note that the programme kicks off on 8 May 2025 at 15:00 and concludes on 11 May 2025 at 12:30.
The ADHD General Assembly will take place on 8 May 2025 from 14:00-14:45 exclusively for members of WFADHD.
Thursday, 8 May 2025
Friday, 9 May 2025
Saturday, 10 May 2025
Sunday, 11 May 2025
GA-01 Special Session
- 14:00 - 14:45, Club A
- General Assembly of WFADHD
- Chair(s): Stephen Faraone, USA; Mark Bellgrove, Australia; Jan K. Buitelaar, The Netherlands; Li Yang, People's Republic of China; Manfred Gerlach, Germany
- 15:00 - 16:30, Congress Hall
- Should I need to worry about cardiovascular risks outcomes in my patients with ADHD treated with psychostimulants?
- Chair(s): Samuele Cortese, United Kingdom; Jonna Kuntsi, United Kingdom
- 001 ADHD medications and long-term risk of cardiovascular diseases - Zheng Chang, Sweden
- 002 Long-term cardiovascular safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the ADHD Drugs Use Chronic Effects (ADDUCE) study - Ian Chi Kei Wong, Hong Kong
- 003 ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA): A multi-centre prospective cohort study - Jonna Kuntsi, United Kingdom
- 004 Comparative cardiovascular side effects of medications for ADHD in children, adolescents and adults: Systematic review and network meta-analysis - Samuele Cortese, United Kingdom
- 15:00 - 16:30, Panorama Hall
- The lancet psychiatry series on ADHD
- Chair(s): Luis Augusto Rohde, Brazil; David Coghill, Australia
- 001 Current evidence and gaps on global ADHD and treatment epidemiology - Adrienne Chan, United Kingdom
- 002 What are the real-world long-term impacts of ADHD and its treatment: clinical, societal, and economic, and political implications - Patrick Ip, Hong Kong
- 003 Barriers and facilitators for improving equity of access to ADHD care - Luis Augusto Rohde, Brazil
- 004 Psychoeducation and advocacy - David Coghill, Australia
- 15:00 - 16:30, North Hall
- ADHD and global crises
- Chair(s): Jeffrey Newcorn, USA; Thomas Müller, Switzerland
- 001 Prenatal exposure to a natural disaster and early development of psychiatric disorders during the preschool years: stress in pregnancy study - Jeffrey Newcorn, USA
- 002 The effect of COVID-19 Pandemic on ADHD - Mark Bellgrove, Australia
- 003 ADHD and climate change - Thomas Müller, Switzerland
- 15:00 - 16:30, South Hall 2A
- Navigating ADHD in the perinatal period
- Chair(s): Kathrine Bang Madsen, Denmark; Lotta Borg Skoglund, Sweden
- 001 It’s all in your head: Hormonal changes across the female reproductive life - Helena Kopp Kallner, Sweden
- 002 Maternal mental health in the perinatal period: Challenges and strategies for women with ADHD - Lotta Borg Skoglund, Sweden
- 003 Short and long-term outcomes for infants exposed to ADHD medications in utero - Kathrine Bang Madsen, Denmark
- 004 ADHD medication use during pregnancy: Balancing benefits and risks - Jacqueline Mallory Cohen, Norway
- 15:00 - 16:30, South Hall 2B
- Joint Symposium of the Affiliated Societies of the World Federation of ADHD
- Chair(s): Sandra Kooij, The Netherlands; Arnstein Mykletun, Norway
- 001 (Not) sleeping and suffering: the interplay between AD(H)D, sleep disorders and psychiatric comorbidity - Dora Wynchank, The Netherlands
- 002 The effect of light therapy on ADHD symptoms in adults - Sandra Kooij, The Netherlands
- 003 Is getting an ADHD-diagnosis harmful or beneficial for children in the grey zone for the diagnosis - Arnstein Mykletun, Norway
- 004 The usual suspects and beyond – decontextualization as explanation for the suboptimal uptake of parenting interventions - Tycho Dekkers, The Netherlands
- 15:00 - 16:30, Club A
- Inflammation and ADHD: The neurobiological mechanisms and clinical associations
- Chair(s): Iris Manor, Israel; Timothy Nielson, Australia
- 001 Association of maternal autoimmune disease with ADHD in children - Timothy Nielsen, USA
- 002 Evaluation of maternal inflammation as a marker of future offspring ADHD symptoms: A prospective investigation - Iris Manor, Israel
- 003 Inflammation: An underlying factor linking ADHD and Asthma Symptoms? - Douglas Teixeira Leffa, USA
- 16:30 - 17:00, Late Breaking Stage (2nd Floor)
Exploring chronic emotional burden as a pathway to depression and anxiety in adolescents with ADHD: A focus beyond emotional control deficits
Moderators: Arthur Caye, Brazil; Katherine Ellison, USA
Discussant: Edmund Sonuga-Barke, United Kingdom
- 17:00 - 18:30, Congress Hall
- Clinical dilemmas in treating patients with medication
- Chair(s): David Coghill, Australia; Jeffrey Newcorn, USA
- 001 What makes and how to approach ADHD complex cases? - Jeffrey Newcorn, USA
- 002 Are drug holidays a valid strategy in ADHD treatment - David Coghill, Australia
- 003 Treating ADHD refractory cases - Samuele Cortese, United Kingdom
- 17:00 - 18:30, Panorama Hall
- Multi-component cognitive behavioural therapy for ADHD: From preschool to adulthood
- Chair(s): Margaret Sibley, USA; Jinsong Zhang, People's Republic of China
- 001 New forest parenting program for preschool children with ADHD in China - Jinsong Zhang, People's Republic of China
- 002 Executive skills training (multi-component cognitive behavioral therapy to both children and parents) for 6-12 children with ADHD: Face to face and on-line, first dosage and second dose - Ying Qian, People's Republic of China
- 003 Cognitive-behavioral treatments for adolescents with ADHD: A systematic review of the literature - Margaret Sibley, USA
- 004 Cognitive-behavioral treatments for adults with ADHD: Systematic review with meta-analysis - Carlos López Pinar, Spain
- 17:00 - 18:30, North Hall
- ADHD: Why are we waiting and what are you going to do about this?
- Chair(s): Sven Bölte, Sweden; Anita Thapar, United Kingdom
- 001 Experiences of being on a waiting list and ideas on what might help - Ceri Reed, United Kingdom
- 002 Waiting for Godot: Can technology help expedite ADHD diagnosis? - Chris Hollis, United Kingdom
- 003 Should non-stimulants be the first medication option for adult ADHD? Lessons from a nurse-led primary-care service - John Ringhisen, USA
- 004 ADHD in Sweden: Policy impacts on waiting lists - Sven Bölte, Sweden
- 17:00 - 18:30, South Hall 2A
- Hazard environmental exposure and the development of ADHD: Evidence from large population study
- Chair(s): Takuya Saito, Japan; Li Yang, People's Republic of China
- 001 Environmental pollution exposure and ADHD symptoms: Progress in the Hokkaido study - Takuya Saito, Japan
- 002 Prenatal opioid exposure and subsequent risk of ADHD: nationwide birth cohort study in South Korea - Jiseung Kang, Republic of Korea
- 003 An umbrella review of evidence on the association between environmental pollutant exposure and neurodevelopmental disorders - Li Yang, People's Republic of China
- 17:00 - 18:30, South Hall 2B
- Neurodiversity approach: Evidence for positive and strength focused aspects in ADHD
- Chair(s): Martine Hoogman, The Netherlands; Edmund Sonuga-Barke, United Kingdom
- 001 Positive attitudes towards ADHD among diagnosed individuals: Divergent influences across symptoms - Nitzan Shahar, Israel
- 002 Quantification of potential strengths in adults with ADHD - Martine Hoogman, The Netherlands
- 003 Distracted, hyperactive, and thriving: Factors supporting successful functioning in ADHD across the adult lifespan - Brandy Callahan, Canada
- 004 I would never give up my ADHD – high-functioning ADHD - Myriam Bea, Germany
- 17:00 - 18:30, Club A
- ADHD in college-aged adults
- Chair(s): Kevin M. Antshel, USA; Jason Bantjes, South Africa
- 001 Why focusing attention on ADHD is integral to porting student mental health and academic success in South Africa Universities - Jason Bantjes, South Africa
- 002 ADHD in college students with sexual/gender minority identities - Kevin M. Antshel, USA
- 003 How effective and specific is extended time for college students? A randomized clinical trial - Lui Martins Costa Malcon, Brazil
- 004 Cognitive-behavioral intervention to treat executive dysfunction in college students with ADHD - Sarah O'Neill, USA
- 19:00 - 20:30 Congress Hall
- Opening Ceremony
- 001 Opening Statement & Lifetime Achievement Award(s) - Stephen Faraone, USA
- 002 Experiences as an adult with ADHD raising a (now grown) adult with ADHD - Katherine Ellison, USA
- 003 Interview with Anita Thapar to get a child psychiatrist’s perspectives - Katherine Ellison, USA; Anita Thapar, United Kingdom
PL-01 Plenary Session
- 08:30 - 10:00, Congress Hall
Translating ADHD research to clinical world- Chair(s): Stephen Faraone, USA; Luis Augusto Rohde, Brazil
- 001 What clinicians need to know about ADHD genetics? - Stephen Faraone, USA
- 002 Non-pharmacological treatment for ADHD: what is almost there? - Margaret Sibley, USA
- 003 Digital solutions in the assessment and treatment of ADHD: What already helps clinicians? - Manfred Döpfner, Germany
- 10:30 - 12:00, Congress Hall
ADHD and trauma across the lifespan- Chair(s): Mark Bellgrove, Australia; Michal Goetz, Czech Republic
- 001 What should we make of the reported link between ADHD and maltreatment? - Edmund Sonuga-Barke, United Kingdom
- 002 Understanding ADHD in the context of genetic trauma predictors - Ditte Demontis, Denmark
- 003 Trauma recovery for ADHD with adverse childhood experiences - the work of trauma-focused psychotherapy in the perspective of adaptive information processing - Jinsong Zhang, People's Republic of China
- 15:00 - 16:30, Congress Hall
Female ADHD and the impact of hormones on mood and health across the lifespan- Chair(s): Maxime de Jong, The Netherlands; Lotta Borg Skoglund, Sweden
- 001 Hormonal effects on ADHD across the menstrual cycle and its cognitive and affective mechanisms - Michelle Martel, USA
- 002 Brain fog and worse: Executive dysfunction during menopausal transition in women with ADHD - Dora Wynchank, The Netherlands
- 003 Female Specific Therapy for Women with ADHD (including premenstrual dose increase of stimulant medication, and group therapy for women with ADHD based on awareness of the impact of the cycle on their symptoms - Maxime de Jong, The Netherlands
- 004 First data on self-efficacy and empowerment through self-monitoring of hormonal changes and ADHD-symptoms in women with ADHD - Lotta Borg Skoglund, Sweden
- 15:00 - 16:30, Panorama Hall
ADHD coaching on the rise: Understanding coaches and their role in support- Chair(s): Margaret Sibley, USA; Emily Simonoff, United Kingdom
- 001 Results from the U.S. National Survey on ADHD coaching - Margaret Sibley, USA
- 002 Results from the Australian National Survey on ADHD coaching - David Coghill, Australia
- 003 Understanding recent trends in ADHD coaching - Tamara Rosier, USA
- 004 Building ADHD coaching guidelines - Emily Simonoff, United Kingdom
- 15:00 - 16:30, North Hall
ADHD and substance use disorders- Chair(s): Martin Gignac, Canada; Brooke Molina, USA
- 001 ADHD and substance use disorders: A frequent comorbidity - Martin Gignac, Canada
- 002 The CADDRA ADHD and Substance Use Program - Samuel Chang, Canada
- 003 ADHD and substance use disorder treatment guidelines - Mathias Luderer, Germany
- 004 Psychostimulant medication for ADHD and risk of harmful substance use and diversion: Adolescent attitudes and long-term outcomes and physician clinical practice strategies - Brooke Molina, USA
- 15:00 - 16:30, South Hall 2A
Assessment and management of ADHD in autism spectrum disorders- Chair(s): Jan K. Buitelaar, The Netherlands; Susan Young, United Kingdom
- 001 The neuroanatomical substrates of autism and ADHD and their link to putative genomic underpinnings - Jan K. Buitelaar, The Netherlands
- 002 ADHD and autism symptoms in youth: A network analysis - Guilherme Polanczyk, Brazil
- 003 Assessing the contribution of measures of attention and executive function to diagnosis of ADHD or autism - Kelsey Harkness, Canada
- 004 Guidance for identification and treatment of individuals with ADHD and autism spectrum disorder based upon expert consensus - Susan Young, United Kingdom
- 15:00 - 16:30, South Hall 2B
Novel biological targets and treatment approaches in ADHD- Chair(s): Katya Rubia, United Kingdom; Sarah Kittel-Schneider, Ireland
- 001 Patients in a dish- in vitro models as tools to investigate the etiology of ADHD, leading to new treatment options - Edna Grünblatt, Switzerland
- 002 The impact of the gut microbiome in the pathogenesis of ADHD and therapeutic approaches targeting the gut microbiome - Sarah Kittel-Schneider, Ireland
- 003 Transcranial direct current stimulation as an option to normalize inhibitory-excitatory dysbalance in ADHD patients - Maria Strauß, Germany
- 004 Targeting right prefrontal cortex with fMRI-Neurofeedback and brain stimulation in ADHD - Katya Rubia, United Kingdom
- 15:00 - 16:30, Club A
Early Career Scientist Award Symposium dedicated to Joseph Sergeant- Chair(s): Tobias Banaschewski, Germany; Sven Bölte, Sweden
- 16:45 - 17:45, South Hall 2A
ADHD in older adults - David Goodman, USA
- 16:45 - 17:45, South Hall 2B
Doctor-patient communication from the perspective of doctors, patients and relatives - Myriam Bea, Germany; Margaret Weiss, Canada
- 16:45 - 17:45, Panorama Hall
Clinical tips in assessing and treating children with ADHD - David Coghill, Australia
- 16:45 - 17:45, North Hall
How to treat refractory ADHD? - Samuele Cortese, United Kingdom
- 16:45 - 17:45, Club A
The Challenge of the Neurodiversity Movement - Edmund Sonuga-Barke, United Kingdom
- 16:45 - 17:45, Club B
Assessment and management of sleep challenges in ADHD - Sandra Kooij, The Netherlands
PL-03 Plenary Session
- 08:30 - 10:00, Congress Hall
Are ADHD medication safe? New data of long-term studies- Chair(s): Jan K. Buitelaar, The Netherlands
- 001 In utero exposure to ADHD medication and long-term offspring neurodevelopmental outcomes - Kathrine Bang Madsen, Demark
- 002 Long-term safety of methylphenidate in children and adolescents with ADHD: 2-years outcomes of the ADHD Drugs Use Chronic Effects (ADDUCE) study - Tobias Banaschewski, Germany
- 003 ADHD Medications Use and Risks of mortality and unintentional injuries: A population-based cohort study - Helen-Maria Vasiliadis, Canada
- 10:30 - 12:00, Congress Hall
Does cognitive behavioral therapy adversely encourage patients with ADHD to mask their true selves?- Moderator: Alexandra Philipsen, Germany
- Proponent: Saskia van der Oord, Belgium
- Opponent: Michael Meinzer, USA
- 15:00 - 16:30, Congress Hall
Two treatments better than one? Investigating combined treatments for childhood ADHD- Chair(s): David Daley, United Kingdom; Mark Stein, USA
- 001 Unguided parent mediated self-help interventions for childhood ADHD with or without medication - David Daley, United Kingdom
- 002 Treating parents with ADHD and their young children in urban pediatric primary care: The TPAC hybrid effectiveness-implementation study - Andrea Chronis-Tuscano, USA
- 003 Investigating a combined treatment approach to equip parents and teachers to support children with ADHD in Japan - Gail Tripp, Japan
- 004 The future of combined treatment: What do we know about sequencing treatments for ADHD? - Mark Stein, USA
- 15:00 - 16:30, North Hall
Joint Symposium of the Affiliated Societies of the World Federation of ADHD- Chair(s): Jennifer Crosbie, Canada; Alysa E. Doyle, USA
- 001 Environmental exposures and social determinants of health: Leveraging population data to build precision models of ADHD risk and resilience - Jennifer Crosbie, Canada
- 002 Pre and perinatal health factors, genetic risk, and youth ADHD symptom trajectories: Leveraging a person-specific approach in the Oregon-1000 Cohort - Molly Nikolas, USA
- 003 Stratifying child and adolescent psychiatric outpatients at highest risk for suicidal thoughts and behaviors: Parsing the role of ADHD and other psychopathology - Alysa E. Doyle, USA
- 004 Diagnostic utility of various components of an ADHD assessment: Lessons learned from a collaborative ADHD clinic between the school system and mental Health - Penny Corkum, Canada
- 15:00 - 16:30, South Hall 2A
Is physical activity a treatment option for ADHD?- Chair(s): Simon Cooper, United Kingdom; Alexandra Philipsen, Germany
- 001 Acute effects of physical activity in young people with ADHD - Simon Cooper, United Kingdom
- 002 START - physical exercise and person-centred cognitive skills training as treatment for adult ADHD: Protocol for a randomized controlled trial - Mialinn Arvidsson Lindvall, Sweden
- 003 The current state of research on exercise effects in children and adolescents as well as in adults with ADHD - Alexandra Philipsen, Germany
- 15:00 - 16:30, South Hall 2B
Clinical perspectives on ADHD and antisocial behavior: Risks, strategies, and outcomes- Chair(s): Ylva Ginsberg, Sweden; Wolfgang Retz, Germany
- 001 ADHD and intimate partner violence - Wolfgang Retz, Germany
- 002 ADHD, sexuality and risk for breaking rules - Daniel Turner, Germany
- 003 Predictors for offending in people with ADHD - Ylva Ginsberg, Sweden
- 004 Therapeutic options for offenders with ADHD - Carlos López Pinar, Spain
- 15:00 - 16:30, Club A
Driving infractions and crashes in adults with ADHD vs. control subjects: Role of ADHD persistence, comorbidities and medication treatment- Chair(s): Søren Dalsgaard, Denmark; Lily Hechtman, Canada
- 001 Driving infractions and crashes in adults vs. controls followed prospectively in the Multisite Multimodal study on ADHD (MTA) - Lily Hechtman, Canada
- 002 Double-blind placebo controlled simulated driving study of adults with ADHD - Craig Surman, USA
- 003 Observational data on traffic behaviour in individuals with ADHD and on effects of medication - Søren Dalsgaard, Denmark
- 15:00 - 16:30, Club B
Early Career Scientist Award Symposium dedicated to Joseph Biederman- Chair(s): Stephen Faraone, USA; Luis Augusto Rohde, Brazil
- 16:45 - 17:45, South Hall 2A
The advantages and limitations of drug holidays - Lily Hechtman, Canada
- 16:45 - 17:45, Club B
Assessment strategies of ADHD in adults - Wolfgang Retz, Germany
- 16:45 - 17:45, North Hall
Clinical pearls in managing stimulant side effects - Margaret Weiss, Canada
- 16:45 - 17:45, South Hall 2B
Psychoeducation, cognitive-behavioural treatment and new non-pharmacological interventions for adult ADHD patients - Alexandra Philipsen, Germany
- 16:45 - 17:45, Club A
New perspectives and techniques in the intervention of ADHD - Li Yang, People's Republic of China
GR-01 Grand Round
- 09:00 - 10:30, Congress Hall
Do I have ADHD? Exploring self-referral, trajectories and potential individualization
Moderator: Luis Rode (Brazil)
Presenter: Paulo Mattos (Brazil)
Discussants: Sandra Kooij, The Netherlands; Craig Surman, USA
*** Awarding of Early Career Scientist Awards and Best Poster Prizes ***
- 10:30 - 11:00, Late Breaking Stage (2nd Floor)
Unlocking genetic secrets of ADHD risk through stem cell modeling- Moderator: Arthur Caye, Brazil
Discussant: Mark Bellgrove, Australia
- Moderator: Arthur Caye, Brazil
- 11:00 - 12:30, Congress Hall
Adult ADHD: Essential insights every health professional must know- Chairs: Stephen Faraone, USA; Li Yang, People's Republic of China
- 001 US guidelines for Adult ADHD - David Goodman, USA
- 002 Can telepsychiatry help with ADHD assessment and treatment? - Martin Gignac, Canada
- 003 The TIMESPAN consortium: ADHD medication discontinuation and persistence in adulthood - Ian Chi Kei Wong, Hong Kong